Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer

Background Pelvic magnetic resonance imaging (MRI) and whole-body positron emission tomography-computed tomography (PET-CT) play an important role at primary diagnostic work-up and in detecting recurrent disease in endometrial cancer (EC) patients, however the preclinical use of these imaging methods is currently limited. We demonstrate the feasibility and utility of MRI and dynamic .sup.18F-fluorodeoxyglucose (FDG)-PET imaging for monitoring tumor progression and assessing chemotherapy response in an orthotopic organoid-based patient-derived xenograft (O-PDX) mouse model of EC. Methods 18 O-PDX mice (grade 3 endometrioid EC, stage IIIC1), selectively underwent weekly T2-weighted MRI (total scans = 32), diffusion-weighted MRI (DWI) (total scans = 9) and dynamic .sup.18F-FDG-PET (total scans = 26) during tumor progression. MRI tumor volumes (vMRI), tumor apparent diffusion coefficient values (ADC.sub.mean) and metabolic tumor parameters from .sup.18F-FDG-PET including maximum and mean standard uptake values (SUV.sub.max/SUV.sub.mean), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and metabolic rate of .sup.18F-FDG (MR.sub.FDG) were calculated. Further, nine mice were included in a chemotherapy treatment study (treatment; n = 5, controls; n = 4) and tumor ADC.sub.mean-values were compared to changes in vMRI and cellular density from histology at endpoint. A Mann-Whitney test was used to evaluate differences between groups. Results Tumors with large tumor volumes (vMRI) had higher metabolic activity (MTV and TLG) in a clear linear relationship (r.sup.2 = 0.92 and 0.89, respectively). Non-invasive calculation of MR.sub.FDG from dynamic .sup.18F-FDG-PET (mean MR.sub.FDG = 0.39 [mu]mol/min) was feasible using an image-derived input function. Treated mice had higher tumor ADC.sub.mean (p = 0.03), lower vMRI (p = 0.03) and tumor cellular density (p = 0.02) than non-treated mice, all indicating treatment response. Conclusion Preclinical imaging mirroring clinical imaging methods in EC is highly feasible for monitoring tumor progression and treatment response in the present orthotopic organoid mouse model. Keywords: Preclinical imaging, Endometrial cancer, Organoid-PDX models, Dynamic PET, Translational imaging, Multimodal imaging